Genetic genealogy

Global Prader-Willi Syndrome Market Report 2019: $2110 Million Market Insights, Epidemiology and Forecasts 2018-2028

Retrieved on: 
Thursday, February 21, 2019
Genodermatoses, RTT, Prader, PWS, Genetics, Genetic genealogy, Medical genetics

The "Prader-Willi Syndrome - Market Insights, Epidemiology and Market Forecast-2028" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Prader-Willi Syndrome - Market Insights, Epidemiology and Market Forecast-2028" report has been added to ResearchAndMarkets.com's offering.
  • Prader-Willi Syndrome - Market Insights, Epidemiology and Market Forecast-2028' report delivers an in-depth understanding of the disease, historical & forecasted epidemiology as well as the market trends of Prader-Willi Syndrome in the United States, EU5 (Germany, Spain, Italy, France and United Kingdom), and Japan.
  • The Report also covers current treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assess underlying potential of the market.
  • Expected launch of potential therapies will lead to an increase in the market size of Prader-Willi Syndrome (PWS) in the coming years.

$2.11 Billion Prader-Willi Syndrome Market Insights, 2019: Epidemiology & Market Forecast to 2028 - ResearchAndMarkets.com

Retrieved on: 
Friday, February 15, 2019
Health, Pharmaceutical, Genodermatoses, RTT, PWS, Branches of biology, Prader–Willi syndrome, Prader, Genetics, Genetic genealogy

The "Prader-Willi Syndrome - Market Insights, Epidemiology and Market Forecast to 2028" drug pipelines has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Prader-Willi Syndrome - Market Insights, Epidemiology and Market Forecast to 2028" drug pipelines has been added to ResearchAndMarkets.com's offering.
  • The report provides the current treatment practices, emerging drugs, market share of the individual therapies, current and forecasted market size of Prader-Willi Syndrome (PWS) from 2017 to 2028 segmented by seven major markets.
  • The report also covers current treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assess underlying potential of the market.
  • According to this research, the global market of Prader-Willi Syndrome (PWS) was estimated to be USD 2,110.17 million in 2018.

uBiome Releases New Explorer™ Story to Help Consumers Understand Cardiovascular Wellness

Retrieved on: 
Monday, February 4, 2019
Branches of biology, Microbiology, Citizen science, Genetic genealogy, uBiome, Chemistry, Articles, Trimethylamine N-oxide, Wellness

Individuals with higher levels of TMAO in their blood tend to have lower levels of cardiovascular wellness.

Key Points: 
  • Individuals with higher levels of TMAO in their blood tend to have lower levels of cardiovascular wellness.
  • "uBiome is proud to expand the insights we provide consumers about their personal health and wellness."
  • Since its launch in 2013, Explorer, uBiome's pioneer product, has provided consumers with a tool to understand how their diet and lifestyle play a role in their health and wellness.
  • uBiome combines its patented proprietary precision sequencing with machine learning and artificial intelligence to develop wellness products, clinical tests, and therapeutic targets.

Takeda to Highlight Advancements in Rare Lysosomal Storage Disorders at Global Scientific Meeting

Retrieved on: 
Monday, February 4, 2019
Rare diseases, Lipid storage disorders, Medicine, Genetic genealogy, Medical genetics, Lysosomal storage disease, Leukodystrophy, Metachromatic leukodystrophy, Gaucher's disease, Lysosome, Inborn errors of metabolism, Sphingolipidoses

"This year we are pleased to demonstrate that Takeda is committed to supporting the lysosomal storage disorder community and to advancing treatment in areas of high unmet need," said Hartmann Wellhoefer, M.D., Vice President, Medical Affairs, Rare Disease and Internal Medicine, Global R&D, Takeda.

Key Points: 
  • "This year we are pleased to demonstrate that Takeda is committed to supporting the lysosomal storage disorder community and to advancing treatment in areas of high unmet need," said Hartmann Wellhoefer, M.D., Vice President, Medical Affairs, Rare Disease and Internal Medicine, Global R&D, Takeda.
  • [6]Hunter syndrome affects 1 in 162,000 total live births, and almost exclusively males.3
    Type 1 Gaucher disease is a rare, inherited metabolic condition, and the most common lysosomal disease.
  • [8]
    Metachromatic Leukodystrophy (MLD) is a rare, inherited disorder that affects the central nervous system (CNS).
  • Takeda focuses its R&D efforts on four therapeutic areas: Oncology, Gastroenterology (GI), Neuroscience, and Rare Diseases.

uBiome Awards Grant to Stanford University to Study the Effect of Semen Microbiome on Fertilization and Embryo Development

Retrieved on: 
Thursday, January 31, 2019
Branches of biology, Embryology, Human reproduction, Biology, Assisted reproductive technology, Fertility medicine, Citizen science, Genetic genealogy, uBiome, Embryo quality, Blastocyst, Embryo

The goal of the study is to analyze the impact of the semen microbiome on fertilization, embryo quality, and pregnancy outcomes.

Key Points: 
  • The goal of the study is to analyze the impact of the semen microbiome on fertilization, embryo quality, and pregnancy outcomes.
  • Data collected from the study will include semen microbiome composition from uBiome's patented kits, rates of fertilization per mature oocyte proportion of embryos forming blastocyst per early embryo, a biopsy of embryo, embryo grades, and proportions of euploid/aneuploid blasts per embryo biopsied.
  • "Dr. Behr and Dr. Vaughn are expanding the limited research on the semen microbiome and how it relates to reproduction," said Jessica Richman, PhD, co-founder and CEO of uBiome.
  • About the grant, Dr. Behr said, "We are grateful to receive our grant through uBiome's Microbiome Grant Initiative.

uBiome Awards Grant to University of Tasmania to Study Association Between Gut Microbiota and Cognitive Decline

Retrieved on: 
Friday, January 25, 2019
Branches of biology, Microbiology, Bacteriology, Medical specialties, Environmental microbiology, Citizen science, Genetic genealogy, uBiome, Human microbiota, Gut flora, Microbiota

The team plans to correlate gut microbiota to cognitive function and stress and identify clusters of gut microbiota that may be protective or harmful to cognitive function.

Key Points: 
  • The team plans to correlate gut microbiota to cognitive function and stress and identify clusters of gut microbiota that may be protective or harmful to cognitive function.
  • "The role of the gut microbiota in Alzheimer's disease and dementia is an exciting area of research uBiome is proud to support," said Jessica Richman, PhD, co-founder and CEO of uBiome.
  • "We are honored to collaborate with University of Tasmania researchers for this remarkable study."
  • Awards include patented microbiome sequencing kits, as well as research support in study design, planning, sample collection, and analysis.

Fabry Disease - Pipeline Insight, 2019 - ResearchAndMarkets.com

Retrieved on: 
Thursday, January 24, 2019
Health, Pharmaceutical, Fabry disease, Drug pipeline, Fabry, Organ systems, Genetic genealogy, Medical genetics

The "Fabry Disease - Pipeline Insight, 2019" drug pipelines has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Fabry Disease - Pipeline Insight, 2019" drug pipelines has been added to ResearchAndMarkets.com's offering.
  • Fabry Disease - Pipeline Insight, 2019 offers comprehensive Insight of the pipeline (under development) therapeutics scenario and growth prospects across Fabry Disease development.
  • The report provides detailed coverage of the pipeline landscape for this mechanism of action, equipped with data from multiple sources with complete pipeline analysis by developmental stage, associated indications, route of administration and molecule type.
  • The report assesses the active Fabry Disease pipeline products by developmental stage, product type, molecule type, and administration route.

uBiome Appoints Dr. Julia Oh, PhD, Skin Microbiome Researcher, to its Scientific Advisory Board

Retrieved on: 
Thursday, January 24, 2019
Branches of biology, Microbiology, Bacteriology, Biology, Environmental microbiology, Citizen science, Genetic genealogy, uBiome, Human microbiota, Microorganism, Microbiota

SAN FRANCISCO, Jan. 24, 2019 /PRNewswire-PRWeb/ --uBiome, the leader in microbial genomics, announces the addition of Dr. Julia Oh, PhD, Assistant Professor of Microbiology at the Jackson Laboratory (JAX), to its Scientific Advisory Board.

Key Points: 
  • SAN FRANCISCO, Jan. 24, 2019 /PRNewswire-PRWeb/ --uBiome, the leader in microbial genomics, announces the addition of Dr. Julia Oh, PhD, Assistant Professor of Microbiology at the Jackson Laboratory (JAX), to its Scientific Advisory Board.
  • Joining the board of leading scientists and doctors from around the world, Dr. Oh will bring to uBiome expertise in skin microbial interactions and probiotic treatments for skin and infectious diseases.
  • The appointment will help uBiome continue its advancement in human microbiome research.
  • "We hope to utilize Dr. Oh's expertise with her addition to our advisory board."

Fedr8 Pathway Signs Partnership with Elevator/Fifty/One

Retrieved on: 
Wednesday, January 23, 2019
Academic disciplines, Anthropology, Demography, Genetic genealogy, Human migration, Migration, Articles, Humanities

Elevator/Fifty/One will deliver consulting, software re-development and migration - virtualization services to Fedr8 Pathway's customers and partner ecosystem.

Key Points: 
  • Elevator/Fifty/One will deliver consulting, software re-development and migration - virtualization services to Fedr8 Pathway's customers and partner ecosystem.
  • Elevator/Fifty/One will engage with Fedr8 Pathway to identify and deliver bespoke migration paths to current best of breed migration destinations.
  • Commenting on the tie up, Damion Greef, Fedr8 CEO said;
    "This collaboration with Elevator/Fifty /One, gives Fedr8 Pathway all the professional services required to deliver cloud migrations driven by Green Rain insights.
  • The core mantra of the Fedr8 Pathway is to make informed insightful and rapid decisions to ensure optimisation of the target cloud environment.

Fedr8 Pathway Signs Partnership with Elevator/Fifty/One

Retrieved on: 
Wednesday, January 23, 2019
Anthropology, Demography, Genetic genealogy, Human migration, Migration, Humanities, Human geography

Elevator/Fifty/One will deliver consulting, software re-development and migration - virtualization services to Fedr8 Pathway's customers and partner ecosystem.

Key Points: 
  • Elevator/Fifty/One will deliver consulting, software re-development and migration - virtualization services to Fedr8 Pathway's customers and partner ecosystem.
  • Elevator/Fifty/One will engage with Fedr8 Pathway to identify and deliver bespoke migration paths to current best of breed migration destinations.
  • Commenting on the tie up, Damion Greef, Fedr8 CEO said;
    "This collaboration with Elevator/Fifty /One, gives Fedr8 Pathway all the professional services required to deliver cloud migrations driven by Green Rain insights.
  • The core mantra of the Fedr8 Pathway is to make informed insightful and rapid decisions to ensure optimisation of the target cloud environment.